Search

Search Constraints

You searched for: Author/Creator Ciardiello, Fortunato

Search Results

1. A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine. Issue 6 (28th May 2021)

2. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). (December 2022)

3. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells. Issue 9 (29th May 2013)

4. Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma. Issue 12 (30th September 2019)

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Issue 10066 (21st January 2017)

6. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Issue 6 (June 2019)

7. Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. Issue 5 (19th September 2019)

8. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. (June 2021)

9. Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. (17th February 2016)

10. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. (October 2020)